共 270 条
[1]
Gusterson BA(1992)Prognostic importance of c- J Clin Oncol 7 1049-1056
[2]
Gelber RD(1998)B-2 expression in breast cancer J Clin Oncol 16 1340-1349
[3]
Goldhirsch A(2001)amplification identifies a poor-prognosis group of women with node-negative breast cancer N Engl J Med 344 783-792
[4]
Price KN(2002)Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 J Clin Oncol 20 3106-3113
[5]
Save-Soderborgh J(1999)Effects on Quality of Life of Combined Trastuzumab and Chemotherapy in Women With Metastatic Breast Cancer Oncogene 18 2241-2251
[6]
Anbazhagan R(1998)Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers Cancer Research 58 2825-2831
[7]
Styles J(2001)Recombinant humanized anti-HER2 antibody (Herceptin™) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts J Clin Oncol 19 2722-2730
[8]
Rudenstam CM(2002)Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer Oncologist 7 410-417
[9]
Golouh R(2003)Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2+ metastatic breast cancer J Clin Oncol 21 3965-71
[10]
Reed R(2000)Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel J Clin Pathol 53 890-2